A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab
Latest Information Update: 16 Feb 2023
At a glance
- Drugs Ramucirumab (Primary) ; Ramucirumab (Primary)
- Indications Biliary cancer; Carcinoid tumour; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Urogenital cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 18 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2021 Planned End Date changed from 3 Apr 2021 to 9 May 2021.